OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Headache and Pain is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis	480
Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description	239
Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition	150
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II	109
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study	105
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine	87
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency	84
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study	74
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries	68
Differences in gray matter volume in episodic migraine patients with and without prior diagnosis or clinical care: a cross-sectional study	63
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache	59
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States	58
Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan	57
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation	56
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials	56
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study	55
Characteristics of N400 component elicited in patients who have migraine with aura	49
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks	49
Diagnostic criteria for acute headache attributed to ischemic stroke and for sentinel headache before ischemic stroke	49
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients	48
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine	47
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China	47
Age- and frequency-dependent changes in dynamic contrast perception in visual snow syndrome	45
Primary headaches during the COVID-19 lockdown in Germany: analysis of data from 2325 patients using an electronic headache diary	43
Debate: Are cluster headache and migraine distinct headache disorders?	42

CGRP and PACAP-38 play an important role in diagnosing pediatric migraine	40
Measuring interictal burden among people affected by migraine: a descriptive survey study	40
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine	39
One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey	39
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia	39
Hypoperfusion in nucleus accumbens in chronic migraine using 3D pseudo-continuous arterial spin labeling imaging MRI	36
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results	35
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial	35
Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury	35